Predictors of lung function and its decline in mild to moderate COPD in association with gender: Results from the Euroscop study  by Watson, L. et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 746–753KEYWORD
Gender;
Respirator
symptoms;
Lung funct
BMI;
COPD
0954-6111/$ - s
doi:10.1016/j.r
$The origina
analyses, but h
Correspond
E-mail addrPredictors of lung function and its decline in mild to
moderate COPD in association with gender: Results
from the Euroscop study$
L. Watsona, J.M. Vonka, C.G. Lo¨fdahlb, N.B. Pridec, R.A. Pauwelsd,
L.A. Laitinene, J.P. Schoutena, D.S. Postmaf,, on behalf of the European
Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseaDepartment of Epidemiology and Statistics, University of Groningen, Hanzeplein 1, p/a P1.129B,
9713 GZ Groningen, The Netherlands
bDepartment of Respiratory Medicine, University Hospital Lund, SE-221 85 Lund, Sweden
cRespiratory Division, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK
dDepartment of Respiratory Diseases, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium
eDepartment of Medicine, University Central Hospital, P.O. Box 340, FIN-00029 HUS Helsinki, Finland
fDepartment of Pulmonology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The
Netherlands
Received 20 August 2004; accepted 29 June 2005S
y
ion;
ee front matter & 2005
med.2005.08.004
l study from which thi
ave approved this man
ing author. Tel.: +31 50
ess: d.s.postma@int.azSummary
Background: There is increasing appreciation of gender differences in COPD but
scant data whether risk factors for low lung function differ in men and women. We
analysed data from 3 years follow-up in 178 women and 464 men with COPD,
participants in the Euroscop Study who were smokers unexposed to inhaled
corticosteroids.
Methods: Explanatory variables of gender, age, starting age and pack-years
smoking, respiratory symptoms, FEV1%FVC and FEV1%IVC (clinically important
measures of airway obstruction), body mass index (BMI), and change in smoking
were included in multiple linear regression models with baseline and change in post-
bronchodilator FEV1 as dependent variables.
Results: Reduced baseline FEV1 was associated with respiratory symptoms in men
only. Annual decline in FEV1 was not associated with respiratory symptoms in either
men or women, and was 55ml less in obese men (BMIX30 kg/m2) than men having
normal BMI, an effect not seen in women. It was 32ml faster in women withElsevier Ltd. All rights reserved.
s data is taken, was sponsored by Astra Zeneca, Sweden. The company has not funded these
uscript.
3613532; fax: +31 50 3619320
g.nl (D.S. Postma).
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Predictors of lung function and its decline in COPD 747FEV1%FVComedian than women with less airway obstruction, a larger difference
than in men (8ml per year). It was 17.7ml/year faster when increasing the daily
number of cigarettes by 10 in men only, but not significantly greater than in women.
Conclusion: Respiratory symptoms were associated with reduced baseline FEV1 in
men with COPD. In men, obesity was associated with reduced decline and increasing
the number of cigarettes smoked with increased decline in lung function. In women
more severe airway obstruction was associated with accelerated decline.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
worldwide major cause of morbidity and mortality.
Cigarette smoking is the principal cause of reduced
lung function, the prime characteristic of COPD.1,2
Other factors associated with reduced lung func-
tion and/or accelerated lung function decline in
the general population are gender, body weight,
and respiratory symptoms.3–6
The prevalence of COPD is higher in men than
women, which is generally attributed to higher
historical rates of cigarette smoking in men.
However, some studies suggest that women are
more susceptible to the deleterious effects of
cigarette smoke, which may partly contribute to
an observed recent increase in female prevalence
rates of COPD.7–10 Burrows et al.11 suggested that a
low initial level of lung function would predict
subsequent rapid decline in FEV1 in smokers, the
so-called ‘‘horse racing effect’’ a phenomenon they
found only in men. There are only a few long-
itudinal analyses available which assess gender
differences in the susceptibility to cigarette smoke
and subsequent change in lung functions. The
results of these studies are not consistent12,13 and
given the use of different statistical and design
methodologies they are hard to compare. Thus,
further longitudinal research is required regarding
a possible difference in gender susceptibility to the
harmful effects of smoking.
The Lung Health Study assessed effects of
changes in smoking habits on lung function decline
in established COPD. Women who became sustained
quitters had an average improvement in FEV1%
predicted during the first year that was 2.5 times as
great as the improvement in men.14 Respiratory
symptoms like chronic cough and chronic mucus
hyper secretion have also been associated with
accelerated decline in lung function15 and in-
creased mortality rates in COPD.16 However,
whether this association differs between men and
women is not clear. Furthermore, excess weight
gain has been associated with reduction in lung
function, particularly FVC. The effect was larger in
men,5 possibly due to a central pattern of fatdistribution in men compared with women.17 Given
the paucity of longitudinal data regarding possible
gender differences in predictors of lung function
and its decline in subjects with COPD, we evaluated
smokers with mild to moderate COPD who received
placebo medication during the Euroscop study,
previously published.18Methods
Subjects
The design of the Euroscop study has been
published elsewhere.18 In brief, 39 study centres
in nine European countries participated in a
randomised double-blind, placebo-controlled study
testing twice-daily treatment with 400 mg budeso-
nide (via Turbuhaler) versus placebo. This study
uses patients from the placebo arm only, as we
wished to study the risk factors associated with
decline in lung function that occurs naturally
without any possible influence from inhaled corti-
costeroid. Persons were aged 30–65 years with a
smoking history of at least five pack-years with a
post-bronchodilator FEV1 between 50% and 100%
predicted and the ratio of pre-bronchodilator FEV1
to slow inspiratory vital capacity (IVC) less than 70%
predicted. Increase in FEV1 after inhalation of 1mg
terbutaline had to be o10% of normal predicted
value. Patients with a history of asthma, allergic
rhinitis or who had used oral glucocorticosteroids
for more than six months prior to study entry were
excluded.Clinic visits and spirometry
Baseline data regarding height, weight, smoking
and smoking history were recorded. Subjects were
seen every three months for spirometry and were
followed for three years. Each centre was supplied
with a dry rolling-seal spirometer and the criteria
of the American Thoracic Society were used to
determine FEV1.
19 The spirometry process has been
stated elsewhere,18 the largest values for IVC and
ARTICLE IN PRESS
L. Watson et al.748FEV1 were accepted from three manoeuvres,
provided the second largest measure was within
0.1 L or 5% of the largest. FEV1 was obtained 15min
after the inhalation of 1mg terbutaline. Informa-
tion regarding smoking habit was collected at each
three monthly visit and symptom assessment was
performed at baseline and annually thereafter at
12, 24 and 36 months. The Phadiatop test was used
to detect specific IgE antibodies to a panel of
common inhalant allergens (Pharmacia Upjohn,
Uppsala, Sweden).Statistical analysis
Analyses were performed to measure the associa-
tion of each explanatory variable with level
of post-bronchodilator FEV1 at baseline and sub-
sequent annual decline in post-bronchodilator
FEV1. Explanatory variables included BMI, calcu-
lated as weight (kilograms) divided by height
(metres2) and divided into categories: underweight
X18.5 kg/m2; normal weight ¼ 18.5–24.9 kg/m2;
overweight ¼ 25.0–29.9 kg/m2; obese X30 kg/m2.
The normal weight range was the reference cate-
gory. Other explanatory variables included gender,
age, height, age at starting to smoke, FEV1%IVC
(dichotomised into subjects above and below the
median—women 64.5% and men 63.3%, respec-
tively), FEV1%FVC (dichotomised into subjects above
and below the median, women 65.5% and men
63.7%, respectively), specific IgE, pack-years of
smoking, and change in smoking habit (individual
regression lines of the number of cigarettes smoked
per day against time as a predictor for annual
change in FEV1 only). Current number of cigarettes
smoked was not included in the models as it has high
co-linearity with pack-years and additionally is not
applicable to all participants as some patients may
have stopped smoking at times during the study,
although all patients were smokers at baseline.
Level of reversibility was not included as it was an
inclusion criterion and by definition had to be below
10%. Phadiatop was tested in all models, but the
association with FEV1 at baseline or over time lacked
significance. To limit the loss of degrees of freedom
it was subsequently removed from analyses. The
following respiratory symptoms at baseline were
tested separately in the models (adjusted for age,
height, pack-years smoking, age at starting to smoke
and BMI) to avoid co-linearity: wheeze at any time,
waking with chest tightness, dyspnea at rest,
dyspnea after activity, woken by dyspnea, woken
by coughing, morning cough or phlegm in winter,
cough or phlegm anytime in winter and chronic
mucous hyper secretion (defined as having bothcough and phlegm for 3 months or more in the last
year). Estimates plus 95% confidence intervals (CI)
describe the association between each explanatory
variable and the two outcome variables: baseline
FEV1 and decline in FEV1. Multiple regression
analyses for baseline FEV1 were performed using
ordinary least squares (OLS). Linear mixed effects
models (LMEs) can be used for longitudinal analysis
to assess differences in the effect of a risk factor
over time between men and women for change in
FEV1, but requires use of a three way interaction
term between time, the risk factor and gender. To
simplify the presentation, OLS could be used on the
individual regression slopes (unweighted individual
regression lines of the FEV1 against time), but
outliers in the data can distort the findings. There-
fore, we opted to use robust MM regression on these
individual regression slopes in S-Plus (version 6.1),
due to the minimal influence caused by outlying
data using this method. The robust regression
method uses the MM-estimate computational
strategy proposed by Yohai, Stahel and Zamar
(1991),28 and supported by a number of robustness
experts who participated in the 1989 IMA summer
conference on ‘‘Directions in Robust Statistics
and Diagnostics.’’20 To test for the effect of
each risk factor separately in men and women,
models incorporating gender interaction terms
with each explanatory variable were performed.
Alpha was set at 0.05.Results
Table 1 shows the baseline characteristics of 642
out of the original 643 patients (178 women) who
were randomly assigned to the placebo arm of the
study. One patient was removed from the original
placebo group who was an extreme outlier with 86
pack-years of smoking but still exhibited a 148ml
per year lung function improvement. This one
patient’s values disproportionately affected the
pack year co-efficient and as her lung function
improvements were counter to that expected in
such a heavy smoker, it was decided to exclude her
from analyses. Men were taller, with a larger
weight and BMI and had a higher prevalence of
atopy than women. All participants exhibited
poorly reversible airflow limitation and women
and men showed similar median post-bronchodila-
tor FEV1% predicted values (81.5% and 79.2%
respectively). The prevalence of symptoms was
similar between men and women, except for
phlegm day or night in winter, which had a
significantly higher prevalence in men than in
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Table 1 Baseline characteristics of females and males.
Median (inter-quartile range)
Females ¼ 178 Males ¼ 464 P value
Age (year) 52.0 (46.0–58.0) 54.0 (48.0–58.0) 0.117
Height (cm) 164.0 (160.0–169.0) 176.0 (172.0–180.0) o0.001
Weight (kg) 61.0 (55.0–70.0) 78.0 (70.0–85.0) o0.001
Body mass index (kg/m2) 22.9 (20.5–25.3) 24.7 (22.7–27.1) o0.001
Age start smoking (year) 17.0 (15.0–20.0) 15.0 (14.0–18.0) o0.001
Pack years of smoking (year) 29.5 (21.0–40.0) 38.3 (28.5–51.3) o0.001
Number of cigarettes/day 16.0 (10.0–22.8) 20.5 (10.0–22.0) 0.829
FEV1 (l)
 2.1 (1.7–2.4) 2.8 (2.3–3.2) o0.001
FEV1%predicted
 81.5 (70.6–89.4) 79.2 (68.8–88.3) 0.279
FEV1%IVC
 64.5 (59.1–67.9) 63.3 (57.1–66.9) 0.024
FEV1%FVC
 65.5 (59.8–69.8) 63.7 (58.0–68.4) 0.022
Reversibility % predicted 2.9 (0.0–5.7) 2.7 (0.0–5.1) 0.551
Phadiatop, % positive 9.1 22.6 o0.001
Wheezing at anytime % 60.5 54.1 0.147
Woken with chest tightness% 13.1 11.7 0.630
Attack of dyspnea at rest% 6.2 6.9 0.745
Attack of dyspnea after activity% 39.9 34.6 0.215
Woken by attack of dyspnea % 4.5 4.3 0.919
Woken by an attack of coughing % 55.9 34.7 o0.001
Cough in morning in winter % 54.5 53.4 0.812
Cough day/night in winter % 58.4 48.7 0.027
Phlegm in morning in winter % 41.8 50.4 0.051
Phlegm day/night in winter % 34.8 44.7 0.023
Chronic mucus hypersecretion % 26.6 28.1 0.691
Respiratory function tests performed after dilation with 1mg terbutaline except FEV1%IVC which was performed prior to
dilation.
Predictors of lung function and its decline in COPD 749women (45% versus 35%, respectively). Woken by an
attack of coughing had a lower prevalence in men
than in women (35% versus 56%) as did cough during
the day or night in winter (49% versus 58%). Women
started to smoke at a significantly later age than
men (median 17 versus 15 years) and had a
significantly lower number of pack-years of smoking
(29.5 versus 38.3). All participants had decreased
their daily cigarette consumption during the 6
months prior to randomisation to a median of
16.0 for women and 20.5 for men Of the 642 study
participants, 349 patients continued smoking
throughout the 3 year follow up period. (104 out
of 178 females and 245 out of 464 males). There
was no significant difference over the study period
in the proportions of males and females who
continued to smoke. Only 5 patients (all male) quit
after the baseline visit and sustained quitting
throughout the study. A further 29 (90% male)
patients quit during the study and sustained
quitting for 4 or more visits (1 year) and did not
return to smoking. The remaining patients tried
quitting at various times but always returned to
smoking.Risk factors for baseline level of FEV1
Table 2 illustrates the cross-sectional multiple
regression analysis assessing risk factors associated
with level of baseline FEV1, excluding respiratory
symptoms. Only higher age and lower height were
significantly associated with lower baseline FEV1.
These associations were not different for men and
women.
The association of respiratory symptoms with
baseline FEV1 is shown in Table 3. In men all
respiratory symptoms, except attacks of dyspnea at
rest, exhibited significant negative associations
with baseline FEV1. In women most of these
associations were also negative but none were
statistically significant.Risk factors for change in FEV1 over time
using robust regression
Table 4 shows the results for annual change in FEV1.
Men with a BMIX30 kg/m2 had a significantly lower
decline in FEV1 (55ml per year) compared to men
ARTICLE IN PRESS
Table 3 Respiratory symptoms associated with baseline postbronchodilator FEV1 (ml) for males and females.
Respiratory Symptom Estimate (95% CI)
Females Males Difference between
males and females
Wheezing at any time 43.3 (97.9; 184.4) 139.5 (223.1; 56.0) 182.8 (346.8; 18.8)
Woken with chest
tightness
159.3 (47.7; 366.4) 163.2 (292.9; 33.4) 322.5 (566.9; 78.2)
Attack of dyspnea at rest 47.4 (326.0; 231.3) 54.7 (219.0; 109.5) 7.36 (330.8; 316.1)
Attack of dyspnea after
activity
29.0 (169.0; 111.0) 184.8 (270.4; 99.2) 155.8 (319.8; 8.3)
Woken by an attack of
dyspnea
93.1 (235.1; 421.3) 247.2 (451.2; 43.3) 340.3 (726.7; 46.1)
Woken by an attack of
coughing
21.1 (155.0; 112.7) 188.0 (273.8; 102.3) 166.9 (325.9; 8.0)
Cough in a.m. in winter 39.0 (171.9; 93.9) 239.5 (320.2; 158.8) 200.5 (356.0; 45.0)
Cough day/night in winter 87.1 (219.8; 45.6) 245.6 (326.3; 165.0) 158.5 (313.8; 3.3)
Phlegm in a.m. in winter 49.7 (185.1; 85.7) 186.2 (267.9; 104.6) 136.5 (294.6; 21.6)
Phlegm in day/night in
winter
57.7 (198.0; 82.7) 182.0 (263.6; 100.3) 124.3 (286.7; 38.1)
Chronic mucous
hypersecretion
95.1 (248.8; 58.5) 244.3 (335.5; 153.1) 149.2 (327.8; 29.5)
Estimate is significant at Po0.05. Each model was adjusted for age, height, pack years of smoking, age at starting to smoke
and BMI.
Table 2 Multiple linear regression (OLS) for risk factors associated with baseline postbronchodilator FEV1 (ml).
Estimate (95% CI)
Females Males Difference between
males and females
Age (year) 33.8 (43.7; 23.8) 30.0 (36.0; 24.1) 3.8 (7.9; 15.4)
Height (cm) 31.0 (19.7; 42.2) 38.1 (32.0; 44.3) 7.2 (5.6; 20.0)
Pack years (year) 1.5 (3.3; 6.4) 0.8 (3.1 : 1.42) 2.4 (7.7; 3.0)
Age start smoking (year) 11.0 (8.6; 30.8) 11.5 (0.1; 23.1) 0.48 (22.5; 23.4)
BMI 16–18.5 (kg/m2)y 43.3 (327.3; 240.7) 102.5 (466.6; 261.6) 59.2 (520.9; 402.6)
BMI 25–29.9 (kg/m2)y 48.7 (113.1; 210.5) 7.8 (95.4; 79.8) 56.5 (240.4; 127.4)
BMIX30 (kg/m2)y 156.0 (463.2; 151.2) 158.8 (319.5; 1.9) 2.8 (349.6; 343.9)
Estimate is significant at 0.05.
yCompared to BMI 18.5–24.9 (normal range).
L. Watson et al.750of normal BMI range (18.5–24.9 kg/m2). This effect
was significantly different to women, who did not
exhibit this phenomenon.
The FEV1%FVC4median level at baseline was
significantly associated with change in FEV1 over
time in women who exhibited 31.3ml per year
reduced decline than females below the median
FEV1%FVC. This was not seen in men. This observed
difference between men and women did not reach
statistical significance using a gender interaction
term in the model. Figure 1 illustrates the associa-tion between FEV1%FVC and annual change in FEV1.
If FEV1%IVC was substituted in the model, there was
a trend in the same direction with regard to change
in FEV1 for women (RR 25.5, 95% CI 1.0–52.0) but
not for men (RR 12.9 95% CI 3.8–29.5).
An increase in the number of cigarettes smoked
by 10 per day during each yearly interval was
significantly associated with a steeper decline in
men of 17.7ml per year. There was no significant
association in women and the difference between
men and women was not significant.
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Table 4 Multiple linear regression (RR) for predictors of annual change in FEV1.
Estimate (95% CI)
Females Males Difference between
males and females
Age (year) 0.19 (1.84–2.21) 0.6 (0.57–1.77) 0.40 (1.89–2.7)
FEV1%FVC (4median) 31.33 (4.58–58.09)
 6.77 (9.61–23.15) 24.48 (55.63–6.66)
Pack years (year) 0.12 (1.20–0.97) 0.12 (0.56–0.32) 0.01 (1.03–1.02)
Age start smoking (year) 0.83 (4.81–3.15) 0.79 (3.31–1.71) 0.0 (4.66–4.66)
DCigarettes smoked (10
c/year)y
1.35 (42.00–44.7) 17.73 (34.43–0.14) 18.96 (48.88–10.97)
BMI 16–18.5 (kg/m2)z 11.23 (43.1–65.66) 0.76 (62.30–63.82) 10.49 (93.71–72.73)
BMI 25–29.9 (kg/m2)z 2.22 (32.96–28.51) 9.02 (8.48–26.53) 11.7 (23.31–46.7)
BMIX30 (kg/m2)z 19.57 (76.59–37.44) 52.92 (19.55–86.29) 72.21 (6.22–138.21)
Estimate is significant at 0.05.
yCompared to BMI 18.5–24.9 (normal range).
zChange in cigarettes: increase or decrease of ten per day during the yearly interval.
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males and females.
Predictors of lung function and its decline in COPD 751Pack-years of smoking, age and age at starting to
smoke were not associated with annual change in
FEV1. Respiratory symptoms were tested separately
in the main model and none of them were
significantly associated with annual change in
FEV1 (results not shown).Discussion
This study shows that there are some gender
differences in risk factors for both baseline level
and annual change of lung function in COPD
patients with current mild to moderately severe
airflow limitation and a significant smoking history.
A striking observation is that for all respiratory
symptoms reported, except attacks of dyspnea atrest, men had a reduced FEV1, an effect not seen in
women. Furthermore, men with a BMIX0 kg/m2
had a 55ml reduction in their annual decline in
FEV1 compared to men with BMI in the normal
range, an effect again not observed in women.
Women with less airway obstruction (FEV1%FVC
above the median) had a 32-ml per year reduced
decline in lung function compared to women with
more severe airway obstruction women, a larger
difference than that seen in men (8ml). Increasing
the number of cigarette smoked by 10 per day was
significantly associated with a steeper decline in
men only, although the difference between men
and women was not significant. Pack-years of
smoking and age at starting to smoke surprisingly
were not associated with either baseline FEV1 or its
subsequent decline.Respiratory symptoms and FEV1
Respiratory symptoms generally occurred with a
similar prevalence in men and women, varying from
6 up to 61% depending on the type of symptoms,
but presence of these symptoms was only signifi-
cantly associated with a lower level of lung
function in men. We believe this is the first time
that such a gender effect has been observed in
individuals with established COPD. The Lung Health
Study reported a trend of a somewhat higher
prevalence of symptoms in men, which they
explained by an added contribution of occupational
exposures from dusts and fumes in men and not in
women.21 Our results in individuals with estab-
lished irreversible airflow limitation support
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L. Watson et al.752previous data reporting lower levels of lung
function in symptomatic individuals from general
populations4,15,22 Furthermore, some of these
studies have also reported that this association
was present in men but not women.4,13 Whether
these symptoms are markers of alteration in the
airways is not clear, as the precise pathogenic
mechanisms underlying symptoms such as chronic
phlegm production are not yet known.
We did not find any association between symp-
toms and lung function decline for either men or
women. Thus, despite a gender difference in the
cross-sectional relationship of symptoms with base-
line FEV1 no effect on the subsequent course in
FEV1 was observed. One study reported findings for
men and women similar to ours14 whilst another
found that individuals with wheeze had a less steep
decline.23 However, many of the latter patients
who had severe airflow limitation also had sig-
nificant reversibility. Thus it may well be that the
reported association reflected the inclusion of
asthmatics in that particular study.FEV1%FVC, FEV1%IVC and annual change in
FEV1
Our findings show that, after adjusting for pack-
years of smoking, change in number of cigarettes
smoked and age at starting to smoke, women with
mild airway obstruction, assessed by FEV1%FVC
showed a significantly smaller decline in FEV1 than
women with more severe airway obstruction. Men
did not exhibit this difference. When airway
obstruction was measured by FEV1%IVC we found
a similar trend of a greater difference in decline in
FEV1 between women according to level of airway
obstruction but this effect was again not seen in
men. Connett et al.24 reported that in the Lung
Health Study sustained quitters of smoking gained
more in FEV1% predicted and women made 2.5
times better gain than men. It is possible that our
results could be influenced by smoking cessation
differences between men and women, as more men
were observed to quit than women. We therefore
examined whether the number of quitters by level
of airway obstruction differed between men and
women in our study, which was not the case. Hence
quitting smoking is not likely an explanation for our
observation. Additionally, the inclusion of Dcigar-
ettes smoked (a change of 10 cigarettes per day
during the yearly interval) in our models partly
adjusts for any putative changes in exposure to
cigarettes. The number of sustained quitters in this
population is also very small which makes anysignificant association between quitting and lung
function hard to assess.Smoking and FEV1
Anthonisen et al.25 concluded in a study of the
77.4% surviving participants of the Lung Health
Study that lung function loss is similar between
sexes in patients who continue to smoke and our
findings support this. However, we show that an
increase in the number of cigarettes smoked
resulted in a steeper FEV1 decline in men but not
significantly more so than in women. It is not fully
clear why this would be, given the general held
increased susceptibility to smoking of women. One
simple explanation might be the lower number of
women under study, hence some lack of power. It is
surprising that pack-years smoking or age at
starting to smoke did not detrimentally affect lung
function. However, this Euroscop population had by
definition mild to moderate disease and these
findings may not apply in a more severe population
where pack years might show a stronger associa-
tion. Wang et al. showed that pack-years smoking
was a significant predictor of reduced maximal
level of FEV1 in men but not women between the
ages of 15 and 35.26 Thus it may well be that the
damage caused by cumulative smoke exposure
happens early in men, preventing attainment of
maximum lung function but does not necessarily
contribute to later decrements, which in men
appears to be more affected by amount of current
exposure.
BMI and FEV1
Having a BMIX30 kg/m2 was positively associated
with the annual change in FEV1 in men only i.e. lung
function improved or declined less rapidly in obese
male subjects. Obesity is generally associated with
reduced FEV1 and weight gain has been shown
longitudinally to reduce pulmonary function3,5 Men
in particular are prone to this problem due to a
central pattern of fat distribution that appears to
be age related, being of greater risk prior to 60
years.17,27 However, BMI as a marker of adiposity
cannot differentiate between muscle tissue and
body fat which might affect lung function, but this
study was not designed to assess these outcomes
and no data is available regarding these physical
measurements. Additionally the study did not
assess weight measurements through time so it is
not possible to assess how changes in weight may
have impacted upon the reduced decline in lung
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duals.
In summary, we found gender differences related
to predictors of FEV1 and its subsequent decline in a
population of men and women smokers with mild to
moderate airway obstruction. Respiratory symp-
toms were associated with reduced baseline FEV1 in
men but not women. In men only, FEV1 loss over
time was less with high BMI levels. In women annual
change in FEV1 was associated with the level of
airway obstruction, an effect not seen in men.
Finally increasing the amount of cigarettes smoked
caused a steeper decline in FEV1 in men.Acknowledgements
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